• Disease
  • Postmenopausal
  • Postmenopausal Women
  • Gloria Ann Bachmann

    Prominent publications by Gloria Ann Bachmann

    KOL Index score: 18927

    OBJECTIVE: To evaluate the efficacy of lower doses of conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for relieving vasomotor symptoms and vaginal atrophy.

    DESIGN: A randomized, double-blind, placebo-controlled trial (the Women's Health, Osteoporosis, Progestin, Estrogen study).

    SETTING: Study centers across the United States.

    PATIENT(S): Two thousand, six hundred, seventy-three healthy, postmenopausal women with an intact uterus, including an efficacy-evaluable ...

    Also Ranks for: Lower Doses |  vaginal atrophy |  vasomotor symptoms |  medroxyprogesterone acetate |  cee mpa
    KOL Index score: 17545

    The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is ...

    Also Ranks for: Breast Cancer |  genitourinary syndrome |  gsm women |  quality life |  consensus recommendations
    KOL Index score: 15761

    OBJECTIVE: The aim of this work was to study the role of ospemifene, a novel selective estrogen receptor modulator, in the treatment of vulvar and vaginal atrophy in postmenopausal women with moderate to severe dyspareunia and physiological vaginal changes.

    METHODS: This multicenter phase 3 study used a randomized, double-blind, parallel-group design to compare the efficacy, safety, and tolerability of oral ospemifene 60 mg/day versus placebo. A total of 605 women aged 40 to 80 years who ...

    Also Ranks for: Vaginal Atrophy |  dyspareunia ospemifene |  postmenopausal vulvar |  selective estrogen |  receptor modulator
    KOL Index score: 15676

    Menorrhagia is a very common clinical problem among women of reproductive age and recent studies have suggested that underlying bleeding disorders, particularly von Willebrand's deficiency and platelet function defects, are prevalent in women presenting with menorrhagia. The objective of this study was to determine the utility of the platelet function analyser (PFA-100) and bleeding time (BT) as initial screening tests for underlying bleeding disorders in women with menorrhagia. In this ...

    Also Ranks for: Bleeding Disorders |  women menorrhagia |  platelet function |  pfa100 sensitivity |  reproductive age
    KOL Index score: 15393

    OBJECTIVE: To evaluate the effects of the tissue selective estrogen complex (TSEC) pairing bazedoxifene (BZA) with conjugated estrogens (CE) on sexual function and quality of life in postmenopausal women.

    METHODS: In this 12-week, double-blind, placebo-controlled study, postmenopausal, non-hysterectomized women (n = 652) with symptoms of moderate to severe vulvar/vaginal atrophy were randomized to once-daily treatment with BZA 20 mg/CE 0.45 or 0.625 mg, BZA 20 mg, or placebo. The Arizona ...

    Also Ranks for: Postmenopausal Women |  conjugated estrogens |  sexual function |  vaginal atrophy |  treatment bza
    KOL Index score: 13928

    OBJECTIVE: To assess the relationship between preeclampsia or eclampsia and stroke, myocardial infarction (MI), subsequent cardiovascular outcomes, and long-term survival.

    METHODS: Using the Myocardial Infarction Data Acquisition System in New Jersey (1994-2009), we analyzed cardiovascular outcomes in women with and without preeclampsia or eclampsia and a first MI or stroke but with a hospitalization for a first MI or stroke (analysis 1: MI case group, n=57; MI control group, n=155; ...

    Also Ranks for: Women Preeclampsia |  cardiovascular outcomes |  stroke pregnancy |  myocardial infarction |  case control
    KOL Index score: 13561

    Menorrhagia is a common clinical problem and is unexplained in more than 50% of women. Although studies suggest that von Willebrand's Disease (VWD) is found in a substantial number of women with unexplained menorrhagia, the prevalence of platelet defects in women with menorrhagia is unknown. To determine the prevalence of platelet and other hemostatic defects, we evaluated women ages 17-55 diagnosed with unexplained menorrhagia. Seventy-four women (52 white, 16 black, six other) were ...

    Also Ranks for: Unexplained Menorrhagia |  platelet function |  vwf rco |  blood coagulation |  bleeding time
    KOL Index score: 12431

    OBJECTIVE: The aim of this study was to assess the safety of ospemifene, a novel selective estrogen receptor modulator, for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.

    METHODS: In this multicenter, randomized, double-blind, placebo-controlled, long-term safety extension study, nonhysterectomized women aged 40 to 80 years (n = 180) received daily oral doses of placebo, ospemifene 30 mg/day, or ospemifene 60 mg/day for 40 weeks (continued as blinded ...

    Also Ranks for: Vaginal Atrophy |  postmenopausal women |  ospemifene treatment |  safety assessments |  placebos postmenopause
    KOL Index score: 11304

    INTRODUCTION: Current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) definitions of sexual dysfunction do not identify all sexual problems experienced clinically by women and are not necessarily applicable for biologic or biopsychosocial management of female sexual dysfunction. A unified nomenclature system enables clinicians, researchers, and regulatory agencies to use the same language and criteria for determining clinical end points, assessing research ...

    Also Ranks for: Female Sexual |  arousal disorders |  women health |  orgasm disorder |  based nosology
    KOL Index score: 11174

    OBJECTIVE: To evaluate the endometrial safety of a tissue selective estrogen complex (TSEC; pairing of a selective estrogen receptor modulator [SERM] with estrogens) composed of bazedoxifene/conjugated estrogens (BZA/CE) in postmenopausal women.

    DESIGN: Randomized, double-blind, multicenter, placebo- and active-controlled, phase 3 study (Selective estrogen Menopause And Response to Therapy [SMART]-1).

    SETTING: Outpatient clinical.

    PATIENT(S): Healthy, postmenopausal women (n = 3,397) age ...

    Also Ranks for: Selective Estrogen |  menopausal therapy |  endometrial hyperplasia |  045 bza |  2 years
    KOL Index score: 11051

    OBJECTIVE: Assessment of 12-month safety of ospemifene 60 mg/day for treatment of postmenopausal women with vulvar and vaginal atrophy (VVA).

    METHODS: In this 52-week, randomized, double-blind, placebo-controlled, parallel-group study, women 40-80 years with VVA and an intact uterus were randomized 6 : 1 to ospemifene 60 mg/day or placebo. The primary objective was 12-month safety, particularly endometrial; 12-week efficacy was assessed. Safety assessments included endometrial histology ...

    Also Ranks for: Vaginal Atrophy |  postmenopausal women |  ospemifene placebo |  endometrial histology |  60 day
    KOL Index score: 11012

    We evaluated overactive bladder (OAB) symptoms and sexual and emotional health in sexually active women with OAB/urgency urinary incontinence (UUI) treated with tolterodine extended release (ER). Sexually active women with OAB symptoms were randomized to placebo or tolterodine ER. Five-day bladder diaries, Sexual Quality of Life Questionnaire—Female (SQOL-F), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and Hospital Anxiety and Depression Scale (HAD) were ...

    Also Ranks for: Sexually Active Women |  overactive bladder |  oab symptoms |  benzhydryl compounds |  quality life
    KOL Index score: 10757

    OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of low-dose conjugated estrogens (CE) cream for treatment of atrophic vaginitis.

    METHODS: Postmenopausal women (N = 423) with moderate-to-severe vaginal atrophy were randomized to CE cream 0.3 mg or placebo once daily (21 days on/7 days off) or twice weekly for 12 weeks, followed by open-label treatment with CE cream for 40 weeks consistent with their prior regimen. Primary endpoints were changes in vaginal ...

    Also Ranks for: Conjugated Estrogens |  endometrial safety |  intravaginal aged aged |  52 weeks |  foams jellies vaginitis
    KOL Index score: 10380

    OBJECTIVE: To evaluate the efficacy of two vaginal doses of estradiol (E2) compared with placebo in the treatment of atrophic vaginitis.

    METHODS: In a multi-center, randomized, double-blind, parallel-group study, 230 postmenopausal women received treatment with 25 mcg or 10 mcg E2 or placebo for 12 weeks. Efficacy was measured through composite score of three vaginal symptoms and grading of vaginal health. Additional analyses included maturation of vaginal and urethral mucosa. Safety ...

    Also Ranks for: Vaginal Tablets |  10 mcg |  placebo treatment |  dose estradiol |  12 weeks


    Gloria Ann Bachmann: Influence Statistics

    Sample of concepts for which Gloria Ann Bachmann is among the top experts in the world.
    Concept World rank
    oral ospemifene placebo #1
    pruritus dyspareunia #1
    distressing vasomotor #1
    reporting bleeding patterns #1
    womans views #1
    placebo vmi #1
    conjugated estrogens cream #1
    tvt postmenopausal women #1
    overview etiology #1
    26055 cycles #1
    week endometrial safety #1
    effective longterm ocp #1
    lowdose conjugated estrogens #1
    average tvt #1
    transabdominal ultrasound questionnaire #1
    tol improvements #1
    discussion office staff #1
    attitudes psychological health #1
    76 premenopausal #1
    choinduced hypertriglyceridemia #1
    postreproductive women #1
    sexual function perimenopause #1
    vulvovaginal conditions #1
    hypoandrogenic woman #1
    common operation majority #1
    dyspareunia symptoms #1
    female humans vulvodynia #1
    ospemifene coprimary endpoints #1
    urogenital maturation #1
    tol 24 #1
    continued sexual involvement #1
    balance aging population #1
    contraceptive protection 9921 #1
    failure ubiquitous condition #1
    vulvovaginal dryness #1
    ospemifene 30 #1
    tray instruments #1
    current objective measurements #1
    measured transabdominal #1
    289 recounting exposure #1
    prescribed management plan #1
    hormonal etiologies fsd #1
    adverse genitourinary symptoms #1
    obstacles sexual health #1
    vaginal symptoms efficacy #1
    progestinonly implants depots #1
    atrophic vaginitis efficacy #1
    insertion sexual #1
    impact pathophysiological factors #1

    Key People For Postmenopausal Women

    Top KOLs in the world
    Jane A Cauley
    hip fracture older women breast cancer
    Jo Ann E Manson
    breast cancer postmenopausal women type 2 diabetes
    Steven Ron Cummings
    hip fracture breast cancer older women
    Elizabeth L Barrett‐Connor
    rancho bernardo study postmenopausal women cognitive function
    Marcia L Stefanick
    postmenopausal women physical activity breast cancer
    Walter Churchill Willett
    breast cancer type 2 diabetes coronary heart disease

    Gloria Ann Bachmann:Expert Impact

    Concepts for whichGloria Ann Bachmannhas direct influence:Postmenopausal women,  Vaginal atrophy,  Urogenital atrophy,  Sexual function,  Transabdominal ultrasound,  Female athletes,  Sexual dysfunction,  Genitourinary syndrome.

    Gloria Ann Bachmann:KOL impact

    Concepts related to the work of other authors for whichfor which Gloria Ann Bachmann has influence:Postmenopausal women,  Sexual dysfunction,  Vaginal atrophy,  Hot flashes,  Breast cancer,  Menopausal symptoms,  Hormone therapy.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Department Obstetrics, Gynecology and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. | The Women’s Health Institute and the Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers Ro